Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Emphysema

ClinicalTrials.gov lists 494 trials for Emphysema or a narrower condition beneath it. Aeris Therapeutics has the most among industry and government lead sponsors, with 17.

MeSH D004646 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 34 Phase 1/2 Phase 1/2 23 Phase 2 Phase 2 68 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 40 Phase 4 Phase 4 43 Not applicable Not applicable 116 Observational Observational 159 Phase 1 Phase 1 34 Phase 1/2 Phase 1/2 23 Phase 2 Phase 2 68 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 40 Phase 4 Phase 4 43 Not applicable Not applicable 116 Observational Observational 159

Trials per phase

1 more section with rows

375 of the 494 trials are tagged with Emphysema itself; the rest are tagged with a narrower condition beneath it.

Get the Emphysema report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Emphysema trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 26

1990: 2 trials (Observational 1, Phase 2 1) 1994: 1 trials (Observational 1) 1995: 1 trials (Observational 1) 1996: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 1999: 4 trials (Observational 2, Not applicable 1, Phase 2 1) 2000: 4 trials (Observational 3, Not applicable 1) 2001: 5 trials (Observational 3, Phase 2 2) 2002: 7 trials (Observational 2, Phase 4 1, Phase 3 3, Phase 2 1) 2003: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 2 2, Phase 1/2 1) 2004: 18 trials (Observational 7, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 1/2 1, Phase 1 2) 2005: 15 trials (Observational 3, Phase 4 1, Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 2) 2006: 14 trials (Observational 3, Phase 4 4, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 2) 2007: 21 trials (Observational 11, Not applicable 2, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2008: 16 trials (Observational 2, Not applicable 3, Phase 4 4, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2009: 25 trials (Observational 7, Not applicable 2, Phase 3 4, Phase 2/3 2, Phase 2 6, Phase 1/2 2, Phase 1 2) 2010: 22 trials (Observational 4, Not applicable 4, Phase 4 2, Phase 2/3 1, Phase 2 6, Phase 1 5) 2011: 20 trials (Observational 5, Not applicable 3, Phase 4 5, Phase 3 4, Phase 2/3 1, Phase 2 2) 2012: 25 trials (Observational 6, Not applicable 6, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1 2) 2013: 23 trials (Observational 6, Not applicable 10, Phase 4 2, Phase 3 4, Phase 1/2 1) 2014: 26 trials (Observational 7, Not applicable 9, Phase 4 3, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2015: 16 trials (Observational 6, Not applicable 6, Phase 4 2, Phase 1 2) 2016: 25 trials (Observational 8, Not applicable 8, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1/2 3) 2017: 26 trials (Observational 7, Not applicable 6, Phase 4 7, Phase 2/3 1, Phase 2 3, Phase 1/2 2) 2018: 24 trials (Observational 8, Not applicable 9, Phase 4 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2019: 16 trials (Observational 4, Not applicable 6, Phase 3 1, Phase 2 3, Phase 1 2) 2020: 12 trials (Observational 6, Not applicable 2, Phase 2 2, Phase 1 2) 2021: 18 trials (Observational 9, Not applicable 5, Phase 4 1, Phase 2 2, Phase 1/2 1) 2022: 16 trials (Observational 10, Not applicable 3, Phase 2 2, Phase 1 1) 2023: 20 trials (Observational 7, Not applicable 5, Phase 3 2, Phase 2 4, Phase 1 2) 2024: 23 trials (Observational 6, Not applicable 8, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 3, Phase 1 2) 2025: 17 trials (Observational 5, Not applicable 6, Phase 4 1, Phase 2 1, Phase 1/2 1, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 16
2025 17
2024 23
2023 20
2022 16
2021 18
2020 12
2019 16
2018 24
2017 26

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 18 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 37 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 310 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Emphysema trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 34
Phase 1/2 23
Phase 2 68
Phase 2/3 9
Phase 3 40
Phase 4 43
Not applicable 116
Observational 159
Expanded access 2

How many Emphysema trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 11
Recruiting 56
Enrolling by invitation 5
Active, not recruiting 20
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Emphysema trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Aeris Therapeutics 17
AstraZeneca 16
Grifols Therapeutics LLC 12
National Heart, Lung, and Blood Institute (NHLBI) 11
Boston Scientific Corporation 9

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Emphysema? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Aclidinium 7
Formoterol 6
Arformoterol 6
UMEC 5
SILDENAFIL 3

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Alpha1-antitrypsin 18
Tiotropium bromide via (Spiriva® Handihaler®) 5
Alpha-1 MP 5
Acetazolamide Pill 5
Salmeterol MDI 3

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Emphysema trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Chronic obstructive pulmonary disease 369 23
Pneumonia 254 31
Chronic obstructive pulmonary disorder 95 2
Pneumothorax 95 18
Hospitalization 59 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Emphysema? (126)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Frequency and characteristics of emphysema in adults with FLNA variants: a single-center study. Orphanet journal of rare diseases 2025 Yes
A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema. Respiratory research 2024 Yes
Topologic Parametric Response Mapping Identifies Tissue Subtypes Associated with Emphysema Progression. Academic radiology 2024 Yes
Blood-based Transcriptomic and Proteomic Biomarkers of Emphysema. American journal of respiratory and critical care medicine 2024 Yes
Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE. Annals of the American Thoracic Society 2024 Yes

Showing 5 of 126 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages